Rich Pharmaceuticals Inc. (fka RCHA)

[TradeSmart.ai]

$RCHA Patent on Phorbol Esters as Anti-Neoplastic and White Blood Cell Elevating Agents

patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=6,063,814.PN.&OS=PN/6,063,814&RS=PN/6,063,814


Drug Profile:

Tetradecanoylphorbol acetate - Biosuccess Biotech/Rich Pharmaceuticals

Alternative Names: PD-616; Phorbol 12-myristate 13-acetate; Phorbol myristate acetate; PMA; RP 323; TPA

***At a glance***

Originator: Rutgers; Zhengzhou University

Developer: Biosuccess Biotech; Rich Pharmaceuticals; Rutgers

Class: Antineoplastics; Antiretrovirals; Esters; Small molecules

Mechanism of Action: Apoptosis stimulants; Mitogen-activated protein kinase modulators; Protein kinase C stimulants

Orphan Drug Status No

New Molecular Entity Yes

Available For Licensing Yes

Highest Development Phases:
Phase II - Acute myeloid leukaemia
Phase I/II - Myelodysplastic syndromes
Preclinical - Stroke

adisinsight.springer.com/drugs/800037733

Dr. Numbenjapon specializes in medical oncology, hematology, and stem cell transplantation. He has over 14 years of experience in Hematology and Oncology.

“We are confident that Dr. Numbenjapon is the best and most qualified physician to head our research abroad, and look forward to his guidance as we embark on the next phase of our clinical studies,” said Ben Chang, CEO.

Now that Rich Pharmaceuticals has filed an IND with the FDA and received approval to start phase I/II operations have progressed to the site level at Phramongkutklao Hospital and a full package has been submitted to the hospitals IRB (Review Board). "Rich Pharmaceuticals is pleased to have reached such a milestone and we look forward to patient enrollment at Phramongkutklao Hospital with the help of Dr. Numbenjapon," stated Mr. Chang.

The company also setup a Twitter account in June and posted two tweets yesterday for the first time ever:

$RCHA Rich Pharmaceuticals Announces Institutional Review Board Submission ow.ly/eo6h30dy5zi #oncology #investors #microcaps
2 replies 10 retweets 13 likes

$RCHA Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials http://ow.ly/9Cl530dy57F #Pharmaceuticals #oncology #investors
0 replies 8 retweets 12 likes

https://twitter.com/RCHA_RichPharma

Ben Chang serves as our President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director. Mr. Chang has previously served as the Chief Financial Officer and subsequently President and Chief Operating Officer of Biosuccess Biotech Co. LTD., a biopharmaceutical company based in Los Angeles, California. During his tenure at Biosuccess, his responsibilities included arranging and leading all corporate and financial operations in North America. Mr. Chang started his life-science career as co-founder of Sun-Rich Chemicals, a product development and distribution organization for nutraceuticals. Mr. Chang has over 25 years of pharmaceutical and executive level experience. Mr. Chang also has experience in international banking, venture capital acquisition, finance, and organizational design and operations. Mr. Chang has a Bachelor of Science Degree in Economics from East Carolina University where he focused on accounting and international business.

David Chou, Ph.D. also serves on the Company's Board of Directors. Mr. Chou is a pharmaceutical development expert with more than 25 years of experience and he has led numerous development projects from pre-clinical evaluation stage to product commercialization. Prior to joining Rich Pharmaceuticals, Mr. Chou was the Chief Product Development Officer at Biosuccess Biotech where he led the product development and manufacturing activities for various indications. Before his career with Biosuccess Biotech, Mr. Chou was the Head of CMC (a Vice President level position) at SBIO, Inc. from 2010 to 2012. While at SBIO, he managed the technical development of 4 clinical stage products and made significant contributions to the success of product out-licensing deals with a total value of more than $500 million. From 1998 to 2010, Mr. Chou held director level positions in pharmaceutical development fields at various biopharmaceutical companies including Neurobiological Technologies, PharmaEngine, Oculex and SUGEN and his development portfolios included Sutent® currently marketed by Pfizer and OZURDEX® marketed by Allergan. Prior to his biotech career, Mr. Chou held various management positions at Hoffmann La-Roche for more than 12 years. At Roche, his development team contributed and submitted more than 20 INDs and 6 full NDAs including marketed products such as Xeloda® (Capecitabine), Xenical® (Orlistat) and Hivid® (Zalcitabine). Mr. Chou received a Ph.D. degree in Chemistry from the City University of New York.

The Company also has Richard Salvador (Chief Clinical Officer), Joseph Huffman (Finance Director), Robert Thomas (Chief Operating Officer) and Tsailing Chang (Corporate Secretary).